443 / 1778
•
Phase I study: 19 patients. MTD not determined.
Low
toxicity profile and highly active (90% CR +PR)
(ASCO 2005, abstr 5142)
•
Randomized phase II: 65 patients stage IIB-IIIB
- RT and weekly cisplatin 35 mg/m2 or weekly gemcitabine 150 mg/m2.
- Similar overall response rate and toxicity
-
Higher CR rate with gemcitabine
(ASCO 2007, abstr 16012)
•
prompted for further trials especially with concurrent and adjuvant
gemcitabine
.
GEMCITABINE
OTHER RADIO-SENSITIZERS